Description |
Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic and anti-tumor[3] properties[1]. Zingerone alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways[2]. Zingerone acts as an anti-mitotic agent, and inhibits the growth of neuroblastoma cells[3].
|
Target |
NF-κB[3]
|
In Vitro |
Zingerone is a nontoxic methoxyphenol with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic properties[1]. Zingerone (0-2 mM) decreases neruoblastoma cell survival[3]. Zingerone (0-2 mM) reduces cyclin D1 expression, increases cleavage of caspase-3 and PARP-1 in BE(2)-M17 cells[3].
|
In Vivo |
Zingerone (50, 100 mg/kg, p.o. daily for 21 days) protects against alloxan-induced diabetes via alleviation of oxidative stress and inflammation in rat[2]. Zingerone (10 mg/kg, i.p.) inhibits tumor progression through mitotic arrest, failure of cell division, and stimulation of apoptosis[3].
|
Density | 1.1±0.1 g/cm3 |
Boiling Point | 323.0±27.0 °C at 760 mmHg |
Flash Point | 123.7±17.2 °C |
Exact Mass | 194.094299 |
PSA | 46.53000 |
LogP | 0.64 |
Vapour Pressure | 0.0±0.7 mmHg at 25°C |
Storage condition | 2-8°C |